Get started
Author

Juliette Lambert

Observed names: J Lambert, J. Lambert
Institutions: Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital André Mignot, Hôpital Saint-Louis, Centre Hospitalier de Versailles
Observed institutions: Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris Cité, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Université Paris-Saclay, Centre Hospitalier Universitaire de Nice, Centre Hospitalier Universitaire Henri-Mondor, Centre Hospitalier Universitaire de Montpellier, CEA Paris-Saclay - Etablissement de Fontenay-aux-roses, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire de Poitiers, Hôpital André Mignot, Infectious Disease Models and Innovative Therapies, Hôpitaux Universitaires Henri-Mondor, Hôpital Saint-Louis, Equipe de Recherche en Epidémiologie Nutritionnelle, Centre Hospitalier de Versailles, Centre de Recherche Épidémiologie et Statistique, Institut de recherche Saint-Louis
ORCID: 0000-0001-5142-0310
Observed ORCID: 0000-0001-5142-0310
OpenAlex ID: A5080147713
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
2018 · Juliette Lambert, Cécile Pautas, et al. · Haematologica · 383
PDF
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy, for the prediction of subsequent cardiotoxicity
2016 · Clément Charbonnel, Raphaele Convers-Domart, et al. · European Heart Journal - Cardiovascular Imaging · 108
Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study
2022 · Nicolas Duployez, Laëtitia Largeaud, et al. · Blood · 95
PDF
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
2019 · Elise Fournier, Nicolas Duployez, et al. · Blood · 92
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
2020 · Claude Gardin, Cécile Pautas, et al. · Blood Advances · 91
PDF
MRD assessed byWT1andNPM1transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
2014 · Juliette Lambert, Jérôme Lambert, et al. · Oncotarget · 89
PDF
Prognostic significance of concurrent gene mutations in intensively treated patients withIDH-mutated AML: an ALFA study
2021 · Matthieu Duchmann, Jean-Baptiste Micol, et al. · Blood · 70
PDF
Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity
2016 · C. Charbonnel, R. Convers-Domart, et al. · Annales de Cardiologie et d Angéiologie · 58
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia
2020 · Laurène Fenwarth, Xavier Thomas, et al. · Blood · 52
PDF
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
2024 · Patrice Chevallier, Thibaut Leguay, et al. · Journal of Clinical Oncology · 49
UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
2023 · Nicolas Duployez, Loïc Vasseur, et al. · Leukemia · 38
PDF
Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
2020 · Laurène Fenwarth, Elise Fournier, et al. · International Journal of Molecular Sciences · 36
PDF
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO
2022 · Pierre-Yves Dumas, Emmanuel Raffoux, et al. · Leukemia · 34
PDF
Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML
2021 · Juliette Lambert, Jerome Lambert, et al. · Blood Advances · 27
PDF
Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation
2015 · T Marchand, T Lamy, et al. · Leukemia · 26
Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
2020 · Ali Nehme, Hassan Dakik, et al. · Blood Advances · 20
PDF
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
2021 · Cécile Pautas, Emmanuel Raffoux, et al. · Bone Marrow Transplantation · 18
PDF
Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use
2020 · Auriane Lesieur, Xavier Thomas, et al. · Haematologica · 17
PDF
Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study
2024 · Pierre Hirsch, Jérôme Lambert, et al. · Blood Cancer Journal · 16
A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia
2021 · Milena Kohn, Marc Delord, et al. · Haematologica · 15
PDF
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
2021 · Matthieu Duchmann, Orianne Wagner-Ballon, et al. · Leukemia · 15
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
2023 · Loïc Vasseur, Laurène Fenwarth, et al. · Blood Advances · 11
PDF
PPARγ agonists promote the resolution of myelofibrosis in preclinical models
2021 · Juliette Lambert, Joseph Saliba, et al. · Journal of Clinical Investigation · 11
PDF
Anticorps monoclonaux conjugués et bispécifiques en cancérologie – compte rendu de la Journée de Saint Louis 2022
2023 · Florence Ranchon, Étienne Chatelut, et al. · Bulletin du Cancer · 8
Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study
2022 · Antony Ceraulo, Hélène Lapillonne, et al. · Blood Advances · 8
PDF
Works count: 73
Citation count: 1,534
H-index: 18
I10-index: 24
Year
Topic
Type